90Yttriumibritumomab tiuxetan: a novel treatment for non-Hodgkins lymphoma
Authors: Kristie A Blum; Nancy L Bartlett
Source: Expert Opinion on Biological Therapy, Volume 4, Number 8, 1 August 2004 , pp. 1323-1331(9)
Publisher: Informa Healthcare
Abstract:
Indolent non-Hodgkins lymphomas (NHLs) comprise 35 40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90Yttriumibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67 80%, with a median remission duration of ~ 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttriumibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.Keywords: 90Yttriumibritumomab tiuxetan; monoclonal antibody; non-Hodgkins lymphoma; radioimmunoconjugate; radioimmunotherapy
Document Type: Drug Evaluation
DOI: http://dx.doi.org/10.1517/14712598.4.8.1323
Publication date: 2004-08-01
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- ingentaconnect is not responsible for the content or availability of external websites
- In this: publication
- By this: publisher
- In this Subject: Organic Chemistry , Oncology
- By this author: Kristie A Blum ; Nancy L Bartlett

Shopping cart
Receive new issue alert